BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 23333662)

  • 1. Treatment eligibility of patients with chronic hepatitis B initially ineligible for therapy.
    Nguyen NH; Nguyen V; Trinh HN; Lin B; Nguyen MH
    Clin Gastroenterol Hepatol; 2013 May; 11(5):565-71. PubMed ID: 23333662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accuracy of international guidelines for identifying significant fibrosis in hepatitis B e antigen--negative patients with chronic hepatitis.
    Sanai FM; Babatin MA; Bzeizi KI; Alsohaibani F; Al-Hamoudi W; Alsaad KO; Al Mana H; Handoo FA; Al-Ashgar H; Alghamdi H; Ibrahim A; Aljumah A; Alalwan A; Altraif IH; Al-Hussaini H; Myers RP; Abdo AA
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1493-1499.e2. PubMed ID: 23811251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rates of Treatment Eligibility in Follow-Up of Patients with Chronic Hepatitis B (CHB) Across Various Clinical Settings Who Were Initially Ineligible at Presentation.
    Uribe LA; Nguyen N; Kim L; Trinh HN; Wong C; Wong C; Nguyen LH; Nguyen MH
    Dig Dis Sci; 2016 Feb; 61(2):618-25. PubMed ID: 26660679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection.
    Papatheodoridis GV; Chrysanthos N; Hadziyannis E; Cholongitas E; Manesis EK
    J Viral Hepat; 2008 Jun; 15(6):434-41. PubMed ID: 18194171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.
    Ono A; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitou S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H
    J Hepatol; 2012 Sep; 57(3):508-14. PubMed ID: 22659518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir.
    Wang CC; Tseng KC; Peng CY; Hsieh TY; Lin CL; Su TH; Tseng TC; Hsu CS; Lin HH; Kao JH
    J Gastroenterol Hepatol; 2013 Jan; 28(1):46-50. PubMed ID: 22989322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive factors for early HBeAg seroconversion in acute exacerbation of patients with HBeAg-positive chronic hepatitis B.
    Kim HS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
    Gastroenterology; 2009 Feb; 136(2):505-12. PubMed ID: 19101558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significant hepatic histopathology in chronic hepatitis B patients with serum ALT less than twice ULN and high HBV-DNA levels in Indonesia.
    Lesmana CR; Gani RA; Hasan I; Simadibrata M; Sulaiman AS; Pakasi LS; Budihusodo U; Krisnuhoni E; Lesmana LA
    J Dig Dis; 2011 Dec; 12(6):476-80. PubMed ID: 22118698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.
    Yuen MF; Seto WK; Fung J; Wong DK; Yuen JC; Lai CL
    Am J Gastroenterol; 2011 Jul; 106(7):1264-71. PubMed ID: 21364549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B: implications for antiviral therapy.
    Fung J; Seto WK; Lai CL; Yuen J; Wong DK; Yuen MF
    J Hepatol; 2011 Feb; 54(2):195-200. PubMed ID: 21056499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment.
    Fung J; Lai CL; Young J; Wong DK; Yuen J; Seto WK; Yuen MF
    Am J Gastroenterol; 2011 Oct; 106(10):1766-73. PubMed ID: 21826112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B) score in classifying treatment eligibility under 2012 Asian Pacific Association for the Study of the Liver (APASL) guideline for chronic hepatitis B patients.
    Chen TM; Chang CC; Huang PT; Wen CF; Lin CC
    Aliment Pharmacol Ther; 2013 Jan; 37(2):243-51. PubMed ID: 23171385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver histology and HBV DNA levels in chronically HBV infected patients with persistently normal alanine aminotransferase.
    Montazeri G; Rahban M; Mohamadnejad M; Zamani F; Hooshyar A; Fazlolahi A; Abedian S; Ghoujeghi F; Estakhri A; Montazeri F; Razjoyan H; Mamarabadi M; Alimohamadi M; Tavangar SM; Malekzadeh R
    Arch Iran Med; 2010 May; 13(3):193-202. PubMed ID: 20433223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States.
    Tong MJ; Hsien C; Hsu L; Sun HE; Blatt LM
    Hepatology; 2008 Oct; 48(4):1070-8. PubMed ID: 18688879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load.
    Tseng TC; Liu CJ; Yang HC; Su TH; Wang CC; Chen CL; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
    Gastroenterology; 2012 May; 142(5):1140-1149.e3; quiz e13-4. PubMed ID: 22333950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
    Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical relevance of HBV DNA load in patients with chronic hepatitis B infection.
    Madan K; Batra Y; Jha JK; Kumar S; Kalra N; Paul SB; Singh R; Duttagupta S; Panda SK; Acharya SK
    Trop Gastroenterol; 2008; 29(2):84-90. PubMed ID: 18972767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and determinants of spontaneous seroclearance of hepatitis B e antigen and DNA in patients with chronic hepatitis B.
    Yang HI; Hung HL; Lee MH; Liu J; Jen CL; Su J; Wang LY; Lu SN; You SL; Iloeje UH; Chen CJ;
    Clin Gastroenterol Hepatol; 2012 May; 10(5):527-34.e1-2. PubMed ID: 22178461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Level of hepatitis B virus DNA in inactive carriers with persistently normal levels of alanine aminotransferase.
    Chu CM; Chen YC; Tai DI; Liaw YF
    Clin Gastroenterol Hepatol; 2010 Jun; 8(6):535-40. PubMed ID: 20304099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong.
    Chan HL; Leung NW; Hussain M; Wong ML; Lok AS
    Hepatology; 2000 Mar; 31(3):763-8. PubMed ID: 10706570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.